| Page 1282 | Kisaco Research
 
(Old) European Protein Degradation Congress 2021
21-23 Sep 2021
VIRTUAL CONGRESS
Protein degradation has redefined the drug discovery landscape, offering a promising solution in the quest to ‘drug the undruggable’. Whilst over the past few years this field as witnessed unprecedented growth, investment, and intrigue (around €4 billion worth, to be precise), 2021 is set to be another showstopper for targeted protein degradation with 15 compounds predicted to enter the clinic by the end of the year.As we enter a new wave of drug discovery:Explore the clinical viability of protein degraders including discussions on delivery methods, optimisation strategies and DMPK & SAR parametersLearn how multispecifics that form connections between POIs and cellular machinery are expanding drug amenability of proteins in this untapped, new wave of medicine.Reach “undruggable” high-hanging fruit using chemoproteomics platforms including DNA encoded libraries and covalent ligand discovery
 

Robert Brooks

CEO
Alphageneron

Robert Brooks

CEO
Alphageneron

Robert Brooks

CEO
Alphageneron
 

Raphaël Ognar

CEO and Co-founder
NKILT Therapeutics

Raphaël Ognar

CEO and Co-founder
NKILT Therapeutics

Raphaël Ognar

CEO and Co-founder
NKILT Therapeutics
 

Monique Dao

VP, Translational Medicine, Immunology
bit.bio

Monique Dao

VP, Translational Medicine, Immunology
bit.bio

Monique Dao

VP, Translational Medicine, Immunology
bit.bio
 

Mariska ter Haak

Director, Analytical Development
IN8bio

Mariska ter Haak

Director, Analytical Development
IN8bio

Mariska ter Haak

Director, Analytical Development
IN8bio
 

Marc Davies

VP, CAR Engineering
Leucid Bio

Marc Davies

VP, CAR Engineering
Leucid Bio

Marc Davies

VP, CAR Engineering
Leucid Bio
 

John Rossi

VP Translational Medicine
Syncopation Life Sciences

John Rossi

VP Translational Medicine
Syncopation Life Sciences

John Rossi

VP Translational Medicine
Syncopation Life Sciences
 

Frank Borriello

CEO
Alloplex Biotherapeutics

Frank Borriello

CEO
Alloplex Biotherapeutics

Frank Borriello

CEO
Alloplex Biotherapeutics
 

Aviad Pato

Head of Research, Natural Killer Cells
Gamida Cell

Aviad Pato

Head of Research, Natural Killer Cells
Gamida Cell

Aviad Pato

Head of Research, Natural Killer Cells
Gamida Cell
 

Karrie Wong

Director of Cell Therapy
KSQ Therapeutics

Karrie Wong

Director of Cell Therapy
KSQ Therapeutics

Karrie Wong

Director of Cell Therapy
KSQ Therapeutics